In the general news, the bodies of flight MH17 were gathered from the Ukraine and flown back to Amsterdam. Israel shelled Gaza more, killing more than 1,000 civilians, triggering unrest in the West Bank. In the U.S., news was slow as the vacation season hits full steam.
In healthcare business news, earnings continued with mostly strong revenue stories. Gilead’s (GILD) Sovaldi exceeded estimates. Robotic surgery rebounded for ISRG. Multiple sclerosis continues to be a good disease for BIIB. However, struggling were GSK and ZMH. Allergan (AGN) also cut 13% of the workforce. Lastly, JNJ approved a $5 B share buyback.
On the data front, Puma (PBYI) spiked 200% on good data for its drug neratinib treating breast cancer. Inovio (INO) met endpoints in a trial of VGX-3100 to treat cervical cancer. Incyte’s (INCY) Jakafi failed in polycythemia vera failed. Lastly, a landmark head-to-head study on bladder cancer showed no benefit to ISRG’s robots compared to open surgery.
From the FDA, GILD’s Zydelig was approved for leukemia and lymphoma.